Clinical Trial Update: Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment [Phase 3]

View source ↗

Summary

Phase 3 rollover trial to continue benralizumab (Fasenra) in participants who completed a prior study and benefited from treatment; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Granulomatosis with Polyangiitis
• Hypereosinophilic Syndrome

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Status: NOT_YET_RECRUITING